PRESS RELEASE / NEWS
HOMEPRESS RELEASE / NEWS
- 2023.07.28Senior Investigator Morishita to be an invited speaker at the RNA Assay Development & Screening Summit on August 24
- 2023.06.23Veritas In Silico and Takeda Enter Into Collaborative Research and License Agreement for mRNA-Targeted Small Molecule Drugs
- 2023.05.22Oncodesign Services and Veritas In Silico enter into business cooperation on developing mRNA-targeted small molecule drugs
- 2022.12.27RaQualia Pharma and Veritas in Silico enter into a new joint research agreement for mRNA-targeted small molecule drug discovery
- 2022.10.04Veritas In Silico Begins RNase-Recruiting Small Molecule Screening for RIBOTAC Design and Synthesis
- 2021.12.27Veritas In Silico Announces 1.4 Billion JPY (Approx. $12.2 Million) Series C Financing
- 2021.11.25Veritas in Silico Signs Joint Drug Discovery Research Agreement with Shionogi
- 2021.09.02Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-Targeting Small Molecule Drug Discovery
- 2021.07.28Toray and Veritas in Silico Sign Joint Drug Discovery Research Agreement
- 2021.04.20Veritas In Silico signs joint research agreement with Kowa to develop mRNA-targeted novel small molecule drugs
- 2021.03.01Illuminating druggable targets for mRNA-targeted drug discovery: Veritas In Silico unveils new database of structures on human, mouse, and rat mRNAs, “Kizashi 1.1”
- 2020.09.30Senior Investigator Morishita gives oral presentation at Drug Discovery Chemistry 2020
- 2019.12.20Launch of Joint Research with Asahi Kasei Pharma for the Discovery of Novel Small-Molecule Drugs Targeting mRNA
- 2019.12.05Principal Investigator Shino’s poster presentation at the 37th Medicinal Chemistry Symposium
- 2019.11.25Senior Investigator Morishita’s talk at the 7th NovAliX Conference
- 2019.11.05Launch of Joint Research with Teijin Pharma for the Discovery of Novel Small-Molecule Drugs Targeting Nucleic Acids
- 2019.09.06Conclusion of Joint Research Agreement for the Discovery of Novel Small-Molecule Drugs Targeting Nucleic Acids
- 2019.07.09Custom Design & Synthesis of Highly Active Gapmer-Type Antisense Oligonucleotides
- 2018.11.26Receive the Forbes Japan “Mizuho Award”
